NEW YORK (GenomeWeb News) – Genomic Health said Tuesday after the close of the market that sales for its flagship product, the Oncotype Dx breast cancer assay, swelled 81 percent for the second quarter ended June 30, 2008, and the firm cut its net loss 43 percent year over year.
 
Genomic Health reported total revenues of $27.8 million, up 89.1 percent from revenues of $14.7 million in the second quarter of 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.